Genmab A (GMAB) Long-Term Investments (2018 - 2026)
Genmab A's (GMAB) quarterly Long-Term Investments came in at $40.0 million in Q1 2026, up 33.33% YoY from $30.0 million in Q1 2025, and up 8.11% on a QoQ basis from $37.0 million in Q4 2025.
Genmab A (GMAB) Long-Term Investments (2018 - 2026) Analysis & Trends
Genmab A (GMAB) has 7 years of Long-Term Investments data on file, last reported at $40.0 million in Q1 2026.
- Quarterly Long-Term Investments rose 33.33% year-over-year to $40.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $40.0 million (up 33.33% YoY) and the FY2025 annual result came in at $37.0 million, up 15.62% from the prior year.
- Long-Term Investments climbed to $40.0 million in Q1 2026, from $37.0 million in the prior quarter.
- In the past five years, Long-Term Investments ranged from a high of $40.0 million in Q1 2026 to a low of $20.0 million in Q4 2023.
- A 4-year average of $32.9 million and a median of $35.0 million in 2025 frame the typical range for Long-Term Investments.
- Annual changes were most pronounced in 2024 — Long-Term Investments surged 60.0% — and 2025, when it rose 15.62%.
- Tracing GMAB's Long-Term Investments over 4 years: stood at $20.0 million in 2023, then soared by 60.0% to $32.0 million in 2024, then climbed by 15.62% to $37.0 million in 2025, then climbed by 8.11% to $40.0 million in 2026.
- The last three Long-Term Investments figures came in at $40.0 million (Q1 2026), $37.0 million (Q4 2025), and $36.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 372.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.17 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Genmab A | 2.05 Bn | 548.77 Mn | 1.07 Bn | 36.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 36.00 Mn |
| Mar 31, 2026 | 40.00 Mn |
| Dec 31, 2025 | 37.00 Mn |
| Sep 30, 2025 | 36.00 Mn |
| Jun 30, 2025 | 35.00 Mn |
| Mar 31, 2025 | 30.00 Mn |
| Dec 31, 2024 | 32.00 Mn |
| Dec 31, 2023 | 20.00 Mn |
| Sep 30, 2020 | 647.00 |
| Dec 31, 2019 | 149.00 |
| Sep 30, 2019 | -58.74 Mn |
| Dec 31, 2018 | 477.37 Mn |